Avadel Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
29 8월 2017 - 8:30PM
Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that
management will present at the 2017 Wells Fargo Healthcare
Conference on Thursday, September 7, 2017 at 10:35 am EDT.
A live audio webcast of the presentation can be
accessed at the Investor section of the Company’s website,
www.avadel.com. A replay of the webcast will be available on the
Company’s website for 90 days following the event.
About Avadel Pharmaceuticals
plc: Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a
specialty pharmaceutical company that seeks to commercialize
differentiated pharmaceutical products that are safe, effective and
easy to take through formulation development, by utilizing its
proprietary drug delivery technology and in-licensing / acquiring
new products; ultimately, helping patients adhere to their
prescribed medical treatment and see better results. The Company is
headquartered in Dublin, Ireland with operations in St. Louis,
Missouri and Lyon, France. For more information, please visit
www.avadel.com.
Safe Harbor: This release may
include "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
herein that are not clearly historical in nature are
forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," "will," "may," and the negative of
these and similar expressions generally identify forward-looking
statements. All forward-looking statements involve risks,
uncertainties and contingencies, many of which are beyond Avadel's
control and could cause actual results to differ materially from
the results contemplated in such forward-looking statements. These
risks, uncertainties and contingencies include the risks relating
to: (i) inability to finalize terms or otherwise fail to meet
expectations regarding the timing and completion of the definitive
license agreement with Serenity under circumstances requiring us to
pay a termination fee of $10,000,000 to Serenity; (ii) the amount
of the costs, fees, expenses and charges related to the negotiation
of a definitive license agreement; (iii) risks related to the need
for management to divert attention from the Company’s ongoing
business operations due to the negotiation of the definitive
license agreement; and (iv) the other risks, uncertainties and
contingencies described in the Company's filings with the U.S.
Securities and Exchange Commission, including our annual report on
Form 10-K for the year ended December 31, 2016 (all of which
filings are also available on the Company's website), in particular
under the captions “Forward-Looking Statements” and “Risk Factors,”
including without limitation: our dependence on a small number of
products and customers for the majority of our revenues; the
possibility that our Bloxiverz®,Vazculep® and Akovaz® products,
which are not patent protected, could face substantial competition
resulting in a loss of market share or forcing us to reduce the
prices we charge for those products; the possibility that we could
fail to successfully complete the research and development for
pipeline products we are evaluating for potential application to
the FDA pursuant to our "unapproved-to-approved" strategy, or that
competitors could complete the development of such products and
apply for FDA approval of such products before us; our dependence
on the performance of third parties in partnerships or strategic
alliances for the commercialization of some of our products; the
possibility that our products may not reach the commercial market
or gain market acceptance; our need to invest substantial sums in
research and development in order to remain competitive; our
dependence on certain single providers for development of several
of our drug delivery platforms and products; our dependence on a
limited number of suppliers to manufacture our products and to
deliver certain raw materials used in our products; the possibility
that our competitors may develop and market technologies or
products that are more effective or safer than ours, or obtain
regulatory approval and market such technologies or products before
we do; the challenges in protecting the intellectual property
underlying our drug delivery platforms and other products; and our
dependence on key personnel to execute our business plan. Avadel
undertakes no obligation to update its forward-looking statements
as a result of new information, future events or otherwise, except
as required by law.
Contacts:
Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
E-mail: mkanan@avadel.com
Lauren Stival
Sr. Director, Investor Relations and Corporate Communications
Phone: (636) 449-5866
Email: lstival@avadel.com
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024